Session » (1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2011

A Phase 1 placebo controlled, single (SAD) and multiple dose escalation (MAD) safety and pharmacokinetic (PK) study of a novel colchicine analogue ABP-745 in healthy volunteers (HV)

10:30AM-12:30PM: Abstract Number: 2012

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China

10:30AM-12:30PM: Abstract Number: 1997

Bone health in patients with gout using real-world U.S. data

10:30AM-12:30PM: Abstract Number: 2000

Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA

10:30AM-12:30PM: Abstract Number: 2004

Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry

10:30AM-12:30PM: Abstract Number: 2001

Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use

10:30AM-12:30PM: Abstract Number: 1999

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

10:30AM-12:30PM: Abstract Number: 1991

Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate

10:30AM-12:30PM: Abstract Number: 2014

Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data

10:30AM-12:30PM: Abstract Number: 2013

Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial

10:30AM-12:30PM: Abstract Number: 2005

Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis

10:30AM-12:30PM: Abstract Number: 2003

Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data

10:30AM-12:30PM: Abstract Number: 2008

Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)

10:30AM-12:30PM: Abstract Number: 1996

Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.

10:30AM-12:30PM: Abstract Number: 2010

Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli

10:30AM-12:30PM: Abstract Number: 2007

Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model

10:30AM-12:30PM: Abstract Number: 2002

Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk

10:30AM-12:30PM: Abstract Number: 1994

Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study

10:30AM-12:30PM: Abstract Number: 1990

Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout

10:30AM-12:30PM: Abstract Number: 1998

Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies

10:30AM-12:30PM: Abstract Number: 1993

Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout

10:30AM-12:30PM: Abstract Number: 2006

Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1995

The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study

10:30AM-12:30PM: Abstract Number: 1992

Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT

10:30AM-12:30PM: Abstract Number: 2009

Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout

« View all sessions from this meeting